The 26 references in paper N. LOMAKIN V., A. SUMAROKOV B., Yu. DOTSENKO V., I. UCHITEL A., L. BURYACHKOVSKAYA I., Н. ЛОМАКИН В., А. СУМАРОКОВ Б., Ю. ДОЦЕНКО В., И. УЧИТЕЛЬ А., Л. БУРЯЧКОВСКАЯ И. (2017) “ИНДИВИДУАЛЬНЫЙ ПОДХОД К ПРИМЕНЕНИЮ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ. НА ЧТО ОПЕРЕТЬСЯ В РЕШЕНИИ? // INDIVIDUAL APPROACH TO PATIENTS WITH INDICATION FOR ANTIPLATELET THERAPY. WHAT TO RELY ON IN CHOOSING THE THERAPY?” / spz:neicon:aterotromboz:y:2017:i:2:p:70-78

1
Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature, 1962, 194: 927-929.
(check this in PDF content)
2
Orme R, Judge HM, Storey R. Monitoring Antiplatelet Therapy. Semin Thromb Hemost, 2017, 43(3): 311-319.
(check this in PDF content)
3
Wang X, Zhang D, Zhing S, Lai Y. Modifying clopidogrel maintaince doses according to vasodilatator-stimulated phosphoprotein phochorylation index improves clinical outcome in patients with clopidogrel resistance. Clin Cardiol, 2011, 34(5): 332-338.
(check this in PDF content)
4
Bonello L, Camoin-Jau L, Armero S, Com O, Argues S, Burignat-Bonello C, Giacomonu M, Bonello R, Collet F, Rossi P, Barragan P, Dignat-George F, Paganelli F. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol, 2009, 103(1): 5-10.
(check this in PDF content)
5
Valgimigli M, Campo M, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo D, Sabate M, Hamon M, Repetto A, Colangelo S, Brungaletta S, Parinello G, Percolo G, Ferrari R. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R) Investigators. Circulation, 2009, 119(5): 3215-3222.
(check this in PDF content)
6
Ari H, Ozkan H, Karacinar A, Ari S, Kosa V, Bozat T. The EFFect of high-dose Clopidogrel treatment in patients with clopidogrel resistanse (the EFFICIENT trial). Int J Cardiol, 2012, 157(3): 374-380.
(check this in PDF content)
7
Stone G, Witzenbichler B, Weise G, Rinaldi MJ, Neumann F, Metzger D, Henry T, Cox D, Duffy P, Mazzaferri E, Gurbel P, Xu K, Parise H, Kirktane A, Brody B, Mehran R, Stuckey TD, for the ADAPT-DES investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 2013, 382: 614-623.
(check this in PDF content)
8
Christ G, Siller-Matula J, Francesconi M, Deschant C, Podczeck-Schweighofer A. Open individualizing dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open, 2014, 4: e005781.
(check this in PDF content)
9
Breet N, van Werkum J, Bouman H, Kelder J, Ruven H, Bal E, Deneer V, Harmze A, van der Heyden J, Rensing B, Suttorp M, Hackeng C, ten Berg J. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA, 2010, 303(8): 754-762.
(check this in PDF content)
10
Mangiacapra F, Patti F, Barbato F, Peace A, Ricottini E, Vizzi V, Gatto L, DAmbrosio A, De Bruyne B, Di Sciascio A. A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention. Results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. JACC: cardiovascular interventions, 2012, 5(3): 281-289.
(check this in PDF content)
11
Parodi G et al. High residual platelet activity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA, 2011, 306(11): 1215-1223.
(check this in PDF content)
12
Aradi D, Tornyos A, PintОr T, Vorobcsuk A, KЧnyi A, FalukЪzy J, ... & KomЧcsi A. Optimazing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. JACC, 2014, 11: 1061-1070.
(check this in PDF content)
13
Aradi D, Collet JP, Mair J, Plebani M, Merkely B, Jaffe A, ... & Mueller C. Platelet function testing in acute cardiac care-is there a role for prediction or prevention of stent thrombosis and bleeding. Thromb Haemost, 2015, 113(2): 221-230.
(check this in PDF content)
14
Ломакин Н.В., Сумароков А.Б., Бурячковская Л.И. Индивидуализация антитромбоцитарной терапии в эпоху клинических стандартов. Кремлевская медицина, 2015, 3: 151-158.
(check this in PDF content)
15
Междисциплинарный Совет Экспертов Российского общества ангиологов и сосудистых хирургов, Российского научного общества специалистов по рентгеноэндоваскулярной диагностике и лечению, Национальной Ассоциации по борьбе с инсультами, Национального научного общества воспаления. Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию. Рациональная фармакотерапия в кардиологии, 2014, 10(6): 679-687.
(check this in PDF content)
16
Cayla G, Guiset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, ... & Montalescot J. For the ANTARCTIC investigators. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded — endpoint, randomized controlled superiority trial. Lancet, 2016, 388: 2015-2022.
(check this in PDF content)
17
Sibbing D, Massberg S. Antiplatelet strategies in elderly people: still a long way to go. Lancet, 2016, 388(10055): 1962-1964.
(check this in PDF content)
18
Gross L, Aradi D, Sibbing D. Platelet Function Testing in Patientts on Antiplatelet Medications. Seminars Thromb Hemost, 2016, 42(3): 306-320.
(check this in PDF content)
19
Messas N, Tanguay J-F, Lordkipanidze M. Tailored antiplatelet therapy in high-risk ACS patient streated with PCI stenting: lessons from the ANTARCTIC trial. J Thoracic Disease, 2017, 3(2).
(check this in PDF content)
20
Aradi D., Storey RF., Komosci A. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J, 2014, 35: 209-215.
(check this in PDF content)
21
Ferraris V, Saha S, Oestreich J. Update to The Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations. Ann Thorac Surg, 2012, 94: 1761-1781.
(check this in PDF content)
22
Kristensen S. ECS/ESA Guedelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J, 2014, 35(35): 2383-431.
(check this in PDF content)
23
Chinese Society of Cardiology of Chinese Medical Association et al. Chinese expert recommendation on monitoring and management of variability in responsiveness to antiplatelet therapy. Eur Heart J. Suppl., 2015, 17(Suppl B): B5-B12.
(check this in PDF content)
24
Windecker S, Kolh P, Alfonso S Windecker S, Koln P, Filiiatos G, Hamm C, ... & ECS/EACTS Guidelines on myocardial Revascularization. Eur Heart J, 2014, 35(37):
(check this in PDF content)
25
1-2619. 25. Oran I, Cinar C, Bozkaya H, Korkmaz M. Tailoring platelet inhibition according to multiple electrode aggregometry decreases the rate of thrombotic complications after intracranial flow-diverting stent implantation. J Neurointervent Surgery, 2014, С. neurintsurg011023.
(check this in PDF content)
26
Fitchett D, Mazer C, Eikelboom J, Verma S. Antiplatelet therapy and cardiac surgery: Review of recent evidence and clinical implications. Canadian J Cardiol, 2013, 29(9): 1042-1047.
(check this in PDF content)